Five months after COVID crisis, drug sales report growth of 4.5 percent at Rs 13170 crore: AIOCD-AWACS Report
New Delhi: The Indian Pharma Market for the first time has come back very strongly after 5 months of the COVID crisis and registered a growth of 4.5% at Rs 13,170 crore, during September 2020., suggests a recent report by the market research firm AIOCD-AWACS.
A detailed look at therapy wise performance shows cardiac registered a monthly growth of 17.1% compared to 11.5 % in Aug'20, while the Anti-Diabetic registered a growth of 6.5% compared to 1.6% in Aug '20.
The anti-infective drug sales, as well as those of anti-diabetic drugs, gave a prominent push to the overall sale of drugs for the month.
Further, respiratory medicines growth slumps to -10.5% compared to -12.4 % in Aug '20. Post lockdown the struggle for Anti-infectives -11.0% in Aug 20 shows some revival but still, it is at 1.4% in Sep 20. Post-Unlockdown since June, the struggle for anti-infectives -10.2 % in July had continued a negative trend -11 % in August '20 and witnessed a decline in sales.
While associated therapy like Gastro further dips to 5.5 % vs -3.1% in Aug'20, Vitamins have bounced back has growth fantastic growth of 16.3% in Sep Vs 6.2 % Aug 20 and Pain & Analgesics are at -4.3 % in Sep'20 vs -9.8 % in Aug 20.
Drugmakers including Torrent Pharm and Mankind Pharma made it among the top ten rank buckets, while Glenmark slipped to the range of 11- 25 rank buckets. Further, India's 10 largest drugmakers reported sales growth of 3-16 percent, except Sun Pharmaceutical Industries which saw sales fall by 2 percent to Rs 619 crore.
Glenmark Pharmaceuticals, the largest manufacturer of the Covid-19 drug favipiravir, posted a 35% growth in sales at Rs 368 crore, while Ipca Laboratories' sales grew 8.8%, reports Live Mint.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.